Skip to main content
SpringerLink
Log in

Adalimumab/antituberculars

Disseminated tuberculosis and paradoxical reaction in the form of immune reconstitution inflammatory syndrome: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Country of occurrence, reporter country and primary source country not stated. Conference abstract is a part of CHEST 2020 Annual Meeting Abstracts presented in October 2020

Reference

  • Kassapidis V, et al. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME: THE RISK OF ADALIMUMAB CESSATION IN TB TREATMENT. Chest 158 (Suppl.): A526 (plus poster), No. 4, Oct 2020. Available from: URL: http://doi.org/10.1016/j.chest.2020.08.499 [abstract]

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adalimumab/antituberculars. Reactions Weekly 1828, 20 (2020). https://doi.org/10.1007/s40278-020-85096-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-85096-x

Search

Navigation